Using Proton MRS to Predict Response of Vorinostat Treatment in Glioblastoma

Trial Profile

Using Proton MRS to Predict Response of Vorinostat Treatment in Glioblastoma

Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Dec 2012

At a glance

  • Drugs Temozolomide (Primary) ; Vorinostat (Primary)
  • Indications Glioblastoma
  • Focus Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 14 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 14 Jun 2012 Actual end date (May 2012) added as reported by ClinicalTrials.gov.
    • 10 Nov 2011 Planned End Date added to 1 May 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top